Preliminary results from fight-102: a phase 1 study of pemigatinib in Japanese patients with advanced malignancies

被引：1
|
作者：
Kuboki, Yasutoshi [1 ]
Furukawa, Masayuki [2 ]
Takahashi, Yasuo [3 ]
Mizuno, Nobumasa [4 ]
Hara, Hiroki [5 ]
Ueno, Makoto [6 ]
Ioka, Tatsuya [7 ]
Takahashi, Shunji [8 ]
Shimizu, Toshio [9 ]
Lihou, Christine F. [10 ]
Tian, Chenwei [10 ]
Ji, Tao [10 ]
Fujiwara, Yutaka [9 ]
机构：
[1] Natl Canc Cent Hosp East, Kashiwa, Chiba, Japan
[2] Kyushu Canc Ctr, Minami Ku, Fukuoka, Fukuoka, Japan
[3] Hokkaido Canc Ctr, Sapporo, Hokkaido, Japan
[4] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[5] Saitama Canc Ctr, Saitama, Japan
[6] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan
[7] Osaka Int Canc Inst, Osaka, Japan
[8] JFCR, Canc Inst Hosp, Koto Ku, Tokyo, Japan
[9] Natl Canc Ctr, Chuo Ku, Tokyo, Japan
[10] Incyte Corp, Wilmington, DE USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
10.1093/annonc/mdz343.034
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1 - 156
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours
    Doi, T.
    Ohtsu, A.
    Yoshino, T.
    Boku, N.
    Onozawa, Y.
    Fukutomi, A.
    Hironaka, S.
    Koizumi, W.
    Sasaki, T.
    BRITISH JOURNAL OF CANCER, 2012, 107 (03) : 429 - 434
  • [22] Preliminary results from a phase 1/2 study of INCB054828, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced malignancies
    Saleh, Mansoor
    Gutierrez, Martin E.
    Subbiah, Vivek
    Smith, David C.
    Asatiani, Ekaterine
    Lihou, Christine F.
    Zhen, Huiling
    Yeleswaram, Swamy
    Ji, Tao
    Nemunaitis, John
    CANCER RESEARCH, 2017, 77
  • [23] Phase 1 study of bavituximab in advanced solid tumor malignancies: Final results
    Ibrahim, Nuhad
    Wong, Lucas
    Stopeck, Alison
    Rosen, Lee S.
    Gerber, David E.
    Shan, Joseph S.
    CANCER RESEARCH, 2010, 70
  • [24] Safety, PK and preliminary efficacy of talazoparib in Japanese patients with advanced solid tumors; Phase 1 Study
    Naito, Yoichi
    Kuboki, Yasutoshi
    Ikeda, Masafumi
    Harano, Kenichi
    Matsubara, Nobuaki
    Toyoizumi, Shigeyuki
    Oishi, Masayo
    Hori, Natsuki
    Nagasawa, Takashi
    Kogawa, Takahiro
    ANNALS OF ONCOLOGY, 2019, 30
  • [25] Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies
    Shaji K. Kumar
    James Jett
    Randolph Marks
    Ronald Richardson
    Fernando Quevedo
    Timothy Moynihan
    Gary Croghan
    Svetomir N. Markovic
    Keith C. Bible
    Rui Qin
    Angelina Tan
    Julian Molina
    Scott H. Kaufmann
    Charles Erlichman
    Alex A. Adjei
    Investigational New Drugs, 2013, 31 : 1201 - 1206
  • [26] Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies
    Kumar, Shaji K.
    Jett, James
    Marks, Randolph
    Richardson, Ronald
    Quevedo, Fernando
    Moynihan, Timothy
    Croghan, Gary
    Markovic, Svetomir N.
    Bible, Keith C.
    Qin, Rui
    Tan, Angelina
    Molina, Julian
    Kaufmann, Scott H.
    Erlichman, Charles
    Adjei, Alex A.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (05) : 1201 - 1206
  • [27] Pharmacokinetics and pharmacodynamics of pemigatinib, a potent and selective inhibitor of FGFR 1, 2, and 3, in patients with advanced malignancies
    Ji, Tao
    Lihou, Christine
    Asatiani, Ekaterine
    Feliz, Luis
    Overholt, Heather
    Landman, Robert
    Chen, Xuejun
    Yeleswaram, Swamy
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [28] A phase I study of oral administration of MGCD265 in patients with advanced malignancies (study 265-102)
    Heath, E. I.
    LoRusso, P.
    Kurzrock, R.
    Falchook, G. S.
    Maroun, C. R.
    Drouin, M. A.
    Juretic, M.
    Martell, R. E.
    Besterman, J. M.
    Wheler, J. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] Phase I study of MGCD265 administered intermittently to patients with advanced malignancies (Study 265-102)
    Hong, D.
    LoRusso, P.
    Kurzrock, R.
    Maroun, C.
    Mehran, M.
    Drouin, M.
    Martell, R.
    Wheler, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [30] Preliminary results from a phase 1/2 study of INCB054828, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced malignancies
    Saleh, Mansoor
    Gutierrez, Martin
    Subbiah, Vivek
    Smith, David C.
    Feliz, Luis
    Zhen, Huiling
    Ji, Tao
    Nemunaitis, John
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
12345